Cargando…
Macrophage Biomarkers sCD163 and sSIRPα in Serum Predict Mortality in Sarcoma Patients
SIMPLE SUMMARY: About 40 percent of all patients treated with curative intent for a primary sarcoma will experience relapse; therefore, most patients do not survive. Prior studies implementing adjuvant chemotherapy have failed to increase survival rate. To increase the survival of sarcoma patients,...
Autores principales: | Aggerholm-Pedersen, Ninna, Friis, Henriette Nymark, Baad-Hansen, Thomas, Møller, Holger Jon, Sandfeld-Paulsen, Birgitte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000605/ https://www.ncbi.nlm.nih.gov/pubmed/36900335 http://dx.doi.org/10.3390/cancers15051544 |
Ejemplares similares
-
Role of high‑sensitivity C‑reactive protein in patients with sarcoma
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2023) -
Inclusion of Metabolic Tumor Volume in Prognostic Models of Bone and Soft Tissue Sarcoma Increases the Prognostic Value
por: Pedersen, Mette Abildgaard, et al.
Publicado: (2023) -
A Cohort Study of Free Light Chain Ratio in Combination with Serum Protein Electrophoresis as a First-Line Test in General Practice
por: Sandfeld-Paulsen, Birgitte, et al.
Publicado: (2022) -
Targeted Treatment of Soft-Tissue Sarcoma
por: Riskjell, Anne Iren, et al.
Publicado: (2023) -
A New Serum Macrophage Checkpoint Biomarker for Innate Immunotherapy: Soluble Signal-Regulatory Protein Alpha (sSIRPα)
por: Vladimirova, Yoanna V., et al.
Publicado: (2022)